SOMERVILLE, Mass.--(BUSINESS WIRE)-- bluebird bio, Inc. (Nasdaq: BLUE) announced today that it has completed the first commercial cell collection for LYFGENIA (lovotibeglogene autotemcel), a one-time ...
bluebird bio (NASDAQ:BLUE) said it has completed the first commercial cell collection for its one-time gene therapy Lyfgenia for the treatment of sickle cell disease. The patient’s cells were ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results